Jul 16, 2021 02:09 PM (GMT+8) · EqualOcean
From July 17, Roche's innovative anti influenza drug sufuda (Chinese common name: mabaloxavir) was officially launched in Ali health. Ali health will also work with Roche to build an online respiratory center influenza specialist to provide users with influenza knowledge popularization, expert Q & A, medication guidance and other services. Influenza, or "influenza", is an acute respiratory tract infection caused by influenza virus. In severe cases, pneumonia, bronchitis, sinusitis and other complications may result in hospitalization. In case of influenza infection, timely and targeted antiviral treatment is needed. As an innovative drug for the treatment of acute uncomplicated influenza patients aged 12 years and above, including patients with high risk of influenza complications, mabaroxavir is the only single dose oral drug approved for the treatment of influenza at present. It is also the first anti influenza virus drug with a new mechanism of action approved by FDA in recent 20 years. Compared with the traditional oral anti influenza drugs, mabaloxavir only needs to be taken once in the whole course of treatment. It can block the virus replication early, stop the virus detoxification within 24 hours, shorten the infection period and significantly reduce the duration of influenza symptoms. It can benefit both the previously healthy people infected with influenza and the people with high risk of influenza complications. In April this year, sufuda was officially approved by the State Food and drug administration, and has been gradually recognized by Chinese epidemiological experts. It is believed that its launch provides a more convenient, effective and accurate scheme for the originally arduous treatment of influenza. On July 17, Roche chose to launch the innovative drug online in Ali health pharmacy.

This text is a result of machine translation.